CD248 and neoplasm: To characterize a possible CD248 involvement in NSCLC cisplatin chemoresistance, we injected cisplatin (2 mg/kg) into CD248fl/flfsp‐1+/+ (WT) or CD248fl/flfsp‐1cre/+ (cKO) mice with Lewis's xenografts, measured the tumour volume, and generated a tumour growth curve.